

Questions to the Committee

1. Are the available data adequate to support the effectiveness of Dengvaxia for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in persons 9 through 45 years of age with laboratory-confirmed previous dengue infection and living in endemic areas?

Please vote Yes or No.

Questions to the Committee

2. Are the available data adequate to support the safety of Dengvaxia when administered to persons 9 through 45 years of age with laboratory-confirmed previous dengue infection and living in endemic areas?

Please vote Yes or No.



Thank you!